Research and Markets: Neuroendocrine Tumors Pipeline Insights 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/866sjh/neuroendocrine) has announced the addition of the "Neuroendocrine Tumors-Pipeline Insights, 2014" subscription to their offering.

This Neuroendocrine Tumors Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Neuroendocrine Tumors.

This report provides information on the therapeutic development based on the Neuroendocrine Tumors dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:

  1. Neuroendocrine Tumors Overview
  2. Neuroendocrine Tumors Pipeline Therapeutics
  3. Neuroendocrine Tumors Therapeutics under Development by Companies
  4. Neuroendocrine Tumors Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Neuroendocrine Tumors Mid Clinical Stage Products (Phase II)
  7. Comparative Analysis
  8. Neuroendocrine Tumors Early Clinical Stage Products (Phase I and IND Filed)
  9. Comparative Analysis
  10. Neuroendocrine Tumors Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Neuroendocrine Tumors - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Neuroendocrine Tumors - Discontinued Products
  19. Neuroendocrine Tumors - Dormant Products
  20. Companies Involved in Therapeutics Development for Neuroendocrine Tumors
  21. Appendix

For more information visit http://www.researchandmarkets.com/research/866sjh/neuroendocrine

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals